ART Advanced Research Technologies Inc. is engaged in the research, design, development and marketing of optical imaging technologies used in the detection of anomalies. The Company's principal business is the application of optical imaging technology primarily to the biomedical sector. In June 2003, the Company launched a proprietary molecular imaging technology known as SAMI, designed to characterize, visualize and measure cellular and molecular processes and pathways in small animals. The Company is in the process of bringing to market SoftScan, an optical imaging device that uses its imaging technology to detect, diagnose and characterize breast cancer. This product represents an imaging solution for the detection, diagnosis and characterization of breast cancer without the adverse consequences associated with traditional technology. The Company has two wholly owned subsidiaries, SAMI System Inc. and ART Aerospace Research Technologies U.S., Inc.